{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:09:32Z","timestamp":1777572572665,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-015996"],"award-info":[{"award-number":["INV-015996"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>One of the key obstacles to malaria elimination is largely attributed to <jats:italic>Plasmodium vivax\u2019s<\/jats:italic> ability to form resilient hypnozoites in the host liver that cause relapsing infections. As a result, interruption of <jats:italic>P. vivax<\/jats:italic> transmission is difficult. <jats:italic>P. vivax<\/jats:italic> transmission occurs in Duffy-positive individuals and have been mainly thought to be absent in Africa. However, increasing studies using molecular tools detected <jats:italic>P. vivax<\/jats:italic> among Duffy-negative individuals in various African countries. Studies on the African <jats:italic>P. vivax<\/jats:italic> has been severely limited because most of malaria control program focus mainly on falciparum malaria. In addition, there is a scarcity of laboratory infrastructures to overcome the biological obstacles posed by <jats:italic>P. vivax<\/jats:italic>. Herein, we established field transmission of Ethiopian <jats:italic>P. vivax<\/jats:italic> for routine sporozoite supply followed by liver stage infection in Mali. Furthermore, we evaluated local <jats:italic>P. vivax<\/jats:italic> hypnozoites and schizonts susceptibilities to reference antimalarial drugs. The study enabled the assessment of local African <jats:italic>P. vivax<\/jats:italic> hypnozoite production dynamics. Our data displayed the ability of the African <jats:italic>P. vivax<\/jats:italic> to produce hypnozoite forms <jats:italic>ex-vivo<\/jats:italic> at different rates per field isolate. We report that while tafenoquine (1\u00b5M) potently inhibited both hypnozoites and schizont forms; atovaquone (0.25\u00b5M) and the phosphatidylinositol-4-OH kinase (PI4K)-specific inhibitor KDU691 (0.5\u00b5M) showed no activity against hypnozoites forms. Unlike hypnozoites forms, <jats:italic>P. vivax<\/jats:italic> schizont stages were fully susceptible to both atovaquone (0.25\u00b5M) and the (PI4K)-specific inhibitor KDU691 (0.5\u00b5M). Together, the data revealed the importance of the local platform for further biological investigation and implementation of drug discovery program on the African <jats:italic>P. vivax<\/jats:italic> clinical isolates.<\/jats:p>","DOI":"10.1186\/s12879-023-08381-y","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T15:02:27Z","timestamp":1686668547000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Ethiopian Plasmodium vivax hypnozoites formation dynamics and their susceptibility to reference antimalarial drugs"],"prefix":"10.1186","volume":"23","author":[{"given":"Laurent","family":"Dembele","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ousmaila","family":"Diakite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanta","family":"Sogore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soriya","family":"Kedir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatalmoudou","family":"Tandina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Maiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andargie","family":"Abate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lemu","family":"Golassa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdoulaye A.","family":"Djimde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"key":"8381_CR1","doi-asserted-by":"crossref","unstructured":"Howes RE, Battle KE, Mendis KN, Smith DL, Cibulskis RE, Baird JK, et al. Global epidemiology of Plasmodium vivax. Am J Trop Med Hyg. 2016 Dec;28(6 Suppl):15\u201334.","DOI":"10.4269\/ajtmh.16-0141"},{"key":"8381_CR2","unstructured":"World malaria report. 2022 [Internet]. [cited 2023 Apr 19]. Available from: https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2022."},{"key":"8381_CR3","doi-asserted-by":"crossref","unstructured":"Howes RE, Reiner RC, Battle KE, Longbottom J, Mappin B, Ordanovich D et al. Plasmodium vivax Transmission in Africa. PLoS Negl Trop Dis. 2015.","DOI":"10.1371\/journal.pntd.0004222"},{"key":"8381_CR4","doi-asserted-by":"crossref","unstructured":"Campo B, Vandal O, Wesche DL, Burrows JN. Killing the hypnozoite \u2013 drug discovery approaches to prevent relapse in Plasmodium vivax. Pathogens and Global Health. 2015.","DOI":"10.1179\/2047773215Y.0000000013"},{"key":"8381_CR5","doi-asserted-by":"crossref","unstructured":"Nega D, Assefa A, Mohamed H, Solomon H, Woyessa A, Assefa Y et al. Therapeutic efficacy of artemether-lumefantrine (Coartem\u00ae) in treating uncomplicated P. falciparum malaria in Metehara, Eastern Ethiopia: Regulatory clinical study. PLoS ONE. 2016.","DOI":"10.1371\/journal.pone.0154618"},{"key":"8381_CR6","doi-asserted-by":"crossref","unstructured":"Hossain MS, Commons RJ, Douglas NM, Thriemer K, Alemayehu BH, Amaratunga C et al. The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network. Beeson JG, editor. PLOS Medicine. 2020 Nov 19;17(11):e1003393.","DOI":"10.1371\/journal.pmed.1003393"},{"key":"8381_CR7","doi-asserted-by":"crossref","unstructured":"Demb\u00e9l\u00e9 L, Franetich JF, Lorthiois A, Gego A, Zeeman AM, Kocken CHM et al. Persistence and activation of malaria hypnozoites in long-term primary hepatocyte cultures. Nat Med. 2014;20(3).","DOI":"10.1038\/nm.3461"},{"key":"8381_CR8","doi-asserted-by":"crossref","unstructured":"Berman JD. Approval of tafenoquine for malaria chemoprophylaxis. Am J Trop Med Hyg. 2019.","DOI":"10.4269\/ajtmh.19-0001"},{"key":"8381_CR9","doi-asserted-by":"crossref","unstructured":"Flegg JA, Metcalf CJE, Gharbi M, Venkatesan M, Shewchuk T, Sibley CH et al. Trends in antimalarial drug use in Africa. Am J Trop Med Hyg. 2013.","DOI":"10.4269\/ajtmh.13-0129"},{"key":"8381_CR10","unstructured":"Clyde DF. Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug. Bulletin of the World Health Organization; 1981."},{"key":"8381_CR11","doi-asserted-by":"crossref","unstructured":"Chu CS, Bancone G, Nosten F, White NJ, Luzzatto L. Primaquine-induced haemolysis in females heterozygous for G6PD deficiency. Malar J. 2018.","DOI":"10.1186\/s12936-018-2248-y"},{"key":"8381_CR12","doi-asserted-by":"crossref","unstructured":"Baird JK. 8-aminoquinoline therapy for latent malaria. Clin Microbiol Rev. 2019.","DOI":"10.1128\/CMR.00011-19"},{"key":"8381_CR13","volume-title":"The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis","author":"ET Nkhoma","year":"2009","unstructured":"Nkhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Molecules, and Diseases: Blood Cells; 2009."},{"key":"8381_CR14","doi-asserted-by":"crossref","unstructured":"McNamara CW, Lee MCS, Lim CS, Lim SH, Roland J, Nagle A et al. Targeting Plasmodium PI(4)K to eliminate malaria. Nature. 2013.","DOI":"10.1038\/nature12782"},{"key":"8381_CR15","doi-asserted-by":"crossref","unstructured":"Golassa L, White MT. Population-level estimates of the proportion of Plasmodium vivax blood-stage infections attributable to relapses among febrile patients attending Adama Malaria Diagnostic Centre, East Shoa Zone, Oromia, Ethiopia. Malar J 2017 Jul 27;16(1):301.","DOI":"10.1186\/s12936-017-1944-3"},{"key":"8381_CR16","doi-asserted-by":"crossref","unstructured":"Tadesse FG, Slater HC, Chali W, Teelen K, Lanke K, Belachew M et al. The Relative Contribution of Symptomatic and Asymptomatic Plasmodium vivax and Plasmodium falciparum Infections to the Infectious Reservoir in a Low-Endemic Setting in Ethiopia. Clinical Infectious Diseases. 2018 Jun 1;66(12):1883\u201391.","DOI":"10.1093\/cid\/cix1123"},{"key":"8381_CR17","doi-asserted-by":"crossref","unstructured":"Abate A, Bouyssou I, Mabilotte S, Doderer-Lang C, Dembele L, Menard D et al. Vivax malaria in Duffy-negative patients shows invariably low asexual parasitaemia: implication towards malaria control in Ethiopia. Malar J. 2022 Aug 1;21(1):230.","DOI":"10.1186\/s12936-022-04250-2"},{"key":"8381_CR18","doi-asserted-by":"crossref","unstructured":"Abate A, Kedir S, Bose M, Hassen J, Dembele L, Golassa L. Infectivity of Symptomatic Patients and Their Contribution for Infectiousness of Mosquitoes following a Membrane Feeding Assay in Ethiopia. Guler JL, editor. Microbiology Spectrum. 2022 Oct 26;10(5).","DOI":"10.1128\/spectrum.00628-22"},{"key":"8381_CR19","doi-asserted-by":"crossref","unstructured":"Dembele L, Gego A, Zeeman AM, Franetich JF, Silvie O, Rametti A et al. Towards an in vitro model of plasmodium hypnozoites suitable for drug discovery. PLoS ONE. 2011.","DOI":"10.1371\/journal.pone.0018162"},{"key":"8381_CR20","doi-asserted-by":"crossref","unstructured":"Gupta DK, Dembele L, Voorberg-van der Wel A, Roma G, Yip A, Chuenchob V et al. The Plasmodium liver-specific protein 2 (LISP2) is an early marker of liver stage development. Storz G, Krzych U, Prigge S, editors. eLife. 2019 May 16;8:e43362.","DOI":"10.7554\/eLife.43362"},{"key":"8381_CR21","doi-asserted-by":"crossref","unstructured":"Zeeman AM, Lakshminarayana SB, van der Werff N, Klooster EJ, Voorberg-van der Wel A, Kondreddi RR, et al. PI4 kinase is a prophylactic but not radical curative target in Plasmodium vivax-Type Malaria Parasites. Antimicrob Agents Chemother. 2016 May;60(5):2858\u201363.","DOI":"10.1128\/AAC.03080-15"},{"key":"8381_CR22","doi-asserted-by":"crossref","unstructured":"Abate A, Bouyssou I, Mabilotte S, Doderer-Lang C, Dembele L, Menard D et al. Vivax malaria in Duffy-negative patients shows invariably low asexual parasitaemia: implication towards malaria control in Ethiopia. Malaria Journal. 2022 Dec 1;21(1):230.","DOI":"10.1186\/s12936-022-04250-2"},{"key":"8381_CR23","doi-asserted-by":"crossref","unstructured":"Meltzer E, Rahav G, Schwartz E. Vivax Malaria Chemoprophylaxis: The Role of Atovaquone-Proguanil Compared to Other Options. Clinical Infectious Diseases. 2018.","DOI":"10.1093\/cid\/cix1077"},{"key":"8381_CR24","doi-asserted-by":"crossref","unstructured":"Dow GS, Gettayacamin M, Hansukjariya P, Imerbsin R, Komcharoen S, Sattabongkot J et al. Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta). Malar J. 2011.","DOI":"10.1186\/1475-2875-10-212"},{"key":"8381_CR25","doi-asserted-by":"crossref","unstructured":"Mayence A, Eynde JJ, Vanden, Tafenoquine. A 2018 novel FDA-approved prodrug for the radical cure of plasmodium vivax malaria and prophylaxis of malaria. Pharmaceuticals. 2019.","DOI":"10.3390\/ph12030115"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08381-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08381-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08381-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T15:04:32Z","timestamp":1686668672000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08381-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8381"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08381-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,13]]},"assertion":[{"value":"9 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Addis Ababa University, Aklilu Lemma Institute of Pathobiology (reference no. ALIPB IRB\/18\/2012\/20), and the National Research Ethics Review Committee (reference no. MoSHE\/02\/152\/778\/21). Written informed consent was obtained from all participants. The study participants were informed that they could be treated according to the national treatment guideline if positive for malaria. The participants and\/or their guardians were given the right to refuse to take part in the study, as well as to withdraw at any time during the study. No names or identifying information were indicated on the questionnaires, and all subjects were assured of confidentiality throughout the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent participation"}},{"value":"Not Applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"405"}}